AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s share price dropped 4.1% on Thursday . The company traded as low as $3.02 and last traded at $3.02, with a volume of 115,036 shares. The stock had previously closed at $3.15.

ACRX has been the topic of a number of analyst reports. RBC Capital Markets reissued a “positive” rating and issued a $6.00 price target on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 16th. Jefferies Group reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Wednesday, August 10th. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, July 29th. Stifel Nicolaus cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Finally, HC Wainwright reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $7.30.

The firm’s 50-day moving average is $3.33 and its 200-day moving average is $3.33. The firm’s market cap is $138.20 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.02. The company earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. Equities analysts forecast that AcelRx Pharmaceuticals Inc. will post ($0.91) earnings per share for the current year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.